Drug intelligence / Profile preview

Qingbu Weijing Decoction

Development stage: Unknown
Lead developer: Xiyuan Hospital
Administration: Oral

Overview

Qingbu Weijing Decoction is a Traditional Chinese Medicine (TCM) herbal formulation developed by Xiyuan Hospital of China Academy of Chinese Medical Sciences. It is primarily investigated for the treatment of stable bronchiectasis, specifically targeting mucus hypersecretion and the reduction of acute exacerbations. As a decoction, it consists of a complex mixture of botanical extracts intended to modulate airway inflammation and improve respiratory function. It is currently being evaluated in multicenter, randomized, double-blind, placebo-controlled clinical trials in China to assess its efficacy and underlying mechanisms in improving patient outcomes.

Other names: Qingbu Weijing Decoction

Beyond the preview

Go deeper on Qingbu Weijing Decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qingbu Weijing Decoction.

Explore the full profile